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Case presentation
A 33-year-old woman was first seen at another hospital for
evaluation of persistent severe dysuria and frequency. Cys-
toscopy revealed shallow linear ulcers, and a bladder biopsy was
consistent with a diagnosis of interstitial cystitis. Over the next 7
years, multiple cystoscopies with bladder dilatations were car-
ried out in an unsuccessful attempt to relieve her severe symp-
toms. At the end of this 7 year period, an intestinal mucosal
patch was inserted into the bladder but symptoms persisted. The
bladder was removed subsequently, and an ileal loop pouch was
created with both ureters draining into the loop.
In each of the next 4 years, she had three to four symptomatic
urinary tract infections documented by positive urine cultures;
all were treated successfully with sulfonamides or ampicillin ad-
ministered orally. Revision of the ileal conduit was performed on
two occasions but the frequency of infections was unaffected.
The patient was first seen at New England Medical Center
Hospital (NEMCH) 4 years after the creation of the ileal loop. At
that time, she had fever (40.6° C), chills, malaise, and right costo-
vertebral angle tenderness. Urine culture revealed greater than
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100,000 col/mI of a Pseudomonas species and Proteus mirabilis.
She was treated with gentamicin administered intravenously,
and symptoms and signs of infection resolved promptly. Serum
creatinine concentration, measured on several occasions, ranged
from 0.8 to 1.0 mg/100 ml. She was discharged on a regimen of
sulfisoxazole, 4 g/day.
Over each of the next 3 years, the patient had three to five
urinary infections typically manifested by right flank pain, fever,
and chills. Urine cultures usually contained Pseudomonas ae-
ruginosa but occasionally E. co/i or Proteus. She was treated
with 3-week courses of either colistimethate, carbenicillin, or
gentamicin depending on in vitro sensitivities. Each time, thera-
py was followed by prompt resolution of symptoms and tempo-
rary sterilization of her urine. A variety of chronic suppressive
agents, including Mandelamine with ascorbic acid and ampicillin
were used but the frequency of infection did not decrease. Dur-
ing this interval, drug toxicity included vertigo from gentamicin,
which resolved after discontinuing the medication, and a papular
truncal exanthum from carbenicillin. Three years after her first
hospitalization at NEMCH, an iv. urogram demonstrated bilat-
eral calyceal blunting and dilatation of the right renal pelvis and
left ureter. A loopogram" demonstrated retrograde flow into
both ureters without evidence of obstruction. Serum creatinine
concentration was approximately 1.3 mg/l00 ml during this time
period.
Over the next several months, the patient had three separate
episodes of right flank pain, fever, chills, and dysuria. Urine cul-
ture revealed Pseudomonas on each occasion. A renal arteri-
ogram, carried out to assess the possibility of a renal abscess,
demonstrated a marked loss of cortical thickness in the right kid-
ney and an irregular lateral contour of the left kidney. A right
nephrectomy was performed in an effort to remove the presumed
focus of infection. Neither an abscess nor a perinephric collec-
tion was found. Serum creatinine concentration was stable at 1.3
mg/l00 ml several months following nephrectomy.
Over the next 7 years, she continued to have two to three epi-
sodes of shaking chills, fever, and cloudy urine each year. Uri-
nary tract infections were documented by culture, and treatment
included the use of tobramycin, amikacin, and most recently,
pipracillin. Revision of the loop stoma was performed on one
occasion after stenosis was discovered. Since this revision of the
loop stoma, the patient has continued to have recurrent infec-
tions with Kiebsiella and occasionally Pseudomonas. Sulfatri-
methoprim was administered over a prolonged period without a
decrease in the frequency of infections. Over the last II years,
the patient has had approximately 40 documented episodes of
acute pyelonephritis. On only one occasion did she pass
"gravel", and no renal calculi have been visualized on any of the
many i.v. urograms that have been performed. She has been free
of urinary symptoms for the last 4 months while receiving 2 g of
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methenamine hippurate each day, but her urine cultures remain
positive for Kiebsiella. Recent serum creatinine concentrations
have ranged between 0.9 and 1.2 mg/100 ml. The most recent iv.
urogram, done several months ago, revealed no evidence of ob-
struction.
Discussion
DR. EDWARD H. KASS (Professor of Medicine,
Harvard Medical School and Director, Channing
Laboratory); I should like to consider some of the
problems exhibited by this patient and then express
my personal view about how to proceed in this type
of situation. We can assume that this patient had an
extremely painful series of episodes related to inter-
stitial cystitis because it led to the extreme measure
of cure by total cystectomy. Fortunately, interstitial
cystitis is an entity that we encounter only rarely.
We haven't the slightest idea whether it is a single
entity or the expression of multiple entities; we
have only the poorest kind of insight into the rea-
sons why some people—more women than men—
develop interstitial cystitis. Even though the pain
that characterizes that condition is clearly related to
the ulcers, we haven't any real insight into why the
ulcerations appear. The natural history is variable
and the treatment disappointing. There are periods
of remission and of relapse and almost any thera-
peutic maneuver may appear to have some ef-
fectiveness, probably because of the fluctuant na-
ture of the disease. A great deal hinges upon the
nature and severity of the pain. The pain is typically
most severe during voiding and clearly relates in
some fashion to contraction of the bladder. Al-
though agents such as urinary antiseptics and corti-
costeroids have been recommended by some, I
have shied away from any method more drastic
than supportive therapy and local use of various
surface anesthetics in the patients with this disorder
that I have seen. Fortunately, none of my patients
has required cystectomy.
Let us return to the patient. After the cystectomy
and ureteral diversion, she had a long series of
symptomatic urinary infections treated by various
antibiotics. A major question posed by this patient
and the one I should like to address first is; How
should we deal with the problem of chronic recur-
rent infections? With an initial infection, a rational
choice is to use an agent such as ampicillin or a
sulfonamide. The trimethoprim-sulfamethoxazole
combination is also effective; in fact, it may inhibit
even a larger percent of organisms than the others,
but it is also considerably more expensive. Drugs
such as cephalexin, nitrofurantoin, and tetracycline
are all used fairly extensively and each of these has
a certain role in clearing an initial episode of bacte-
riuria.
Not infrequently, however, as in the patient un-
der discussion today, infections recur again and
again and eventually resistant organisms appear.
This patient has an especially difficult problem be-
cause of the presence of an ileal bladder. In such
patients, repeated urine cultures are essential for
optimum management; however, cultures accurate-
ly reflect the urinary tract flora only if the stoma is
cleansed thoroughly with several washings with
soap. The problem in patients with an ileal bladder
is that there is an open communication between the
bladder and the skin surface, and many patients,
like the one described here, develop infections with
resistant organisms, such as Pseudomonas, Ser-
ratia, Proteus, and sometimes anaerobes or Can-
dida. Very often when these resistant organisms ap-
pear, expensive and potentially toxic drugs are ad-
ministered and after a short symptom-free interval,
we find that the patient is reinfected with another
resistant organism.
Are there alternative approaches to managing this
frequent and difficult problem? One method is the
repetitive use of a variety of antimicrobial drugs.
Another method of keeping the urine free of bac-
teria over a long period of time—and the one I fa-
vor—is to use a therapeutic agent with the following
characteristics; first, it must be active against a
wide variety of microbes; second, high enough con-
centrations of the agent should be achieved in the
urine to inhibit colonization of new bacteria and to
kill existing bacteria; third, its toxicity must be low
enough to avoid serious problems during long-term
administration; fourth, it must act on the metabo-
lism of the microbe in a fashion that reduces to van-
ishingly low levels the likelihood that resistant orga-
nisms will appear. Subtances that seem to satisfy all
of these criteria include both mandelic acid and hip-
puric acid.
As you know, mandelic acid is marketed as me-
thenamine mandelate but the methenamine prob-
ably plays only a small part in the drug's therapeutic
effect. Methenamine does release small amounts of
formaldehyde, but most of the formaldehyde com-
bines with high molecular weight materials, particu-
larly urinary uromucoid. The result is that only
small and variable amounts of free formaldehyde
are available for bacterial killing; thus, in my opin-
ion, methenamine alone is not an effective anti-
bacterial agent. The principal ingredient is the man-
delic acid, but everything that I shall say about
mandelic acid is equally true of hippuric acid. What
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is the mechanism of action of these agents and how
do they satisfy the criteria that I have laid out?
These two substances are weak organic acids that
enter bacteria only as the un-ionized form. The
number of un-ionized molecules is entirely depen-
dent on the pKa of the acid and the pH of the urine.
Mandelic acid has a pKa of 3.3 and hippuric acid
has a pKa of 3.8, thus the lower the urine pH, the
greater the number of un-ionized molecules. At a
urine pH of 5.0, for example, the number of un-ion-
ized molecules of mandelic acid is exactly three
times higher than at pH 5.5. Therefore, if the urine
pH is maintained at a low level, the activity of man-
delic acid is substantially potentiated and a smaller
amount of the drug can be ingested by the patient
with the same effect [1, 2].
Before going into details of the therapeutic ap-
proach, let us consider briefly the mechanism of ac-
tion of these agents. The precise mechanisms are
not well worked out, but we know that these agents
act as direct inhibitors of mitochondrial oxygen up-
take in bacteria. When we exposed bacteria to these
drugs under the proper conditions, oxygen uptake
fell immediately to zero. The data are consistent
with a virtually instantaneous inhibition of mito-
chondrial metabolism (Kass and Cohen, unpub-
lished observations).
I might digress a moment to recount the events
that led to the discovery of the urinary antiseptic
properties of hippuric acid. I learned in the late 40's
that many women on Cape Cod and Martha's Vine-
yard took cranberry sauce when they had symp-
toms of urinary tract infections, and the technician
who was working with me at the time confirmed
that this practice was a part of the local folklore. Dr.
Phyllis Bodel, then a senior medical student, car-
ried out a literature search on cranberries and dis-
covered several interesting facts. First, the material
called cran, which is cranberry juice, is an extreme-
ly tart substance with a pH of approximately 2.0.
Cran contains large quantities of an organic acid
called quinic acid, a cyclohexanoic acid. Further-
more, data obtained from feeding cranberry sauce
to a group of student volunteers demonstrated that
the urinary content of hippuric acid rose strikingly
and almost linearly in relationship to the amount
of quinic acid contained in the ingested sauce.
From the structural formula for hippuric acid and
its pKa, it was obvious to us that hippuric acid
was analogous to mandelic acid, and we hypothe-
sized that the hippuric acid shared the same anti-
bacterial mechanism. It took only a day or two to
show that this hypothesis was correct [3]. At the
present time, hippuric acid is on the market: it, too,
is available as the methenamine salt. Of course, the
urine always contains some hippuric acid originat-
ing from dietary sources, but in order to have an
antibacterial effect it is necessary to give additional
quantities and to have a sufficiently low urinary pH.
Thus, mandelic acid or hippuric acid in the form
of the methenamine salt appear to be equally
efficacious. My choice is to select the less ex-
pensive of the two and at the present time generic
methenamine mandelate qualifies. Originally, we
prescribed additional urinary acidifers, such as am-
monium chloride, methionine, or ascorbic acid, but
gave up this practice some years ago because we
appreciated that both mandelic acid and hippuric
acid were hydrogen ion donors and that a substantial
acid load could be provided merely by using larger
doses of the urinary antiseptic itself. Thus, instead
of giving 4 to 5 g of methenamine mandelate daily
along with another source of hydrogen ion, we sim-
ply gave more of the drug itself. We have often used
6 to 9 g and have treated some patients with as
much as 14 g of methenamine mandelate daily [1].
The proper dose is the smallest amount that main-
tains the urine free of bacteria. Our practice is to
start with 3 g daily and then to increase the dose by
1 g every 2 or 3 days until bacteriuria has cleared. In
recent years, I have rarely encountered a patient in
whom we were unable to eliminate bacteriuria with
this approach.
The use of these agents requires considerable in-
teraction with the patient. The patient must be in-
formed that, as the concentration of the drug gets
higher and the urinary pH gets lower, symptoms of
bladder irritation may develop. We teach our pa-
tients to use the ordinary dip-slide to monitor their
progress [4, 5]. If the slide is clear of bacteria, the
patient assumes that bacterial growth is minimal,
but if after proper incubation the slide contains
many "black dots" suggesting a recurrence of bac-
teriuria, the patient sends the slide to us in the mail
for more detailed testing. If these practices are fol-
lowed, the results are usually dramatic. The urine of
patients who have recurrent infection with resis-
tance to the common antibacterial drugs can be
cleared quite regularly. In patients whose urine is
sterilized with mandelic or hippuric acid, it is often
possible after 1 to 2 years of therapy to reduce the
dose and yet keep the urine sterile. We have treated
several hundred patients with this regimen with ex-
cellent results and remarkably few side effects, but I
recommend such therapy only if it is individualized
as I described here. Giving 2 to 3 g daily of either of
An approach to the management of resistant urinary infections 207
these agents and declaring treatment a failure, on
this dose if the urine still contains bacteria is not an
adequate trial, in my opinion.
There are a few situations in which methenamine
mandelate fails. One is when a Proteus or other
urea-splitting organism is generating so much am-
monia that we cannot feed enough hydrogen ion to
lower the urine pH. In this case, the tactic that we
use hasn't been documented on a large enough
scale, and this practice must therefore be consid-
ered unproved. The tactic is to begin methenamine
mandelate in doses as high as 8 g/day and simulta-
neously to administer an appropriate antimicrobial
drug to suppress the bacteria. The working scheme
is a very simple one. If the number of organisms is
reduced by the antibiotic, the amount of ammonia
produced will be less and the mandelic acid can
then acidify the urine. When the bacterial numbers
are reduced by the antibiotic, chosen on the basis of
in vitro sensitivity, the mandelic acid is used to
maintain the suppression.
Returning to the patient under discussion, I am
unhappy, as I am sure you are, about the loss of the
kidney because it appeared to be functioning even if
it was markedly reduced in size. Unilateral pyelone-
phritis is common as a pathologic finding but not as
a microbiologic finding. If ureteral catheters are
placed into the renal pelvis, bacteria are usually
found to be coming from both kidneys if the infec-
tion has been present in either kidney for any period
of time. So, little if anything is solved by removing
one of the kidneys. It seems likely to me that a pro-
gram similar to the one I described today would
have been considerably more effective than the one
employed, namely, the repetitive use of antibiotics.
Questions and Answers
DR. J. P. KASSIRER: Do any of your patients de-
velop metabolic acidosis when large doses of me-
thenamine mandelate are used?
DR. E. H. KASS: Yes, this is an important point.
Patients with normal kidneys who are given methe-
namine mandelate, of course, don't become acido-
tic except under unusual conditions. The major diffi-
culties are encountered in patients who have some
degree of renal insufficiency. Fortunately, these are
also the patients in whom relatively little methena-
mine mandelate may be required to drive the urine
pH down. Even 2 g a day will clear bacteriuria in
some patients with renal insufficiency. They must
be followed closely for evidence of acidosis, how-
ever, and must be warned to seek help if they be-
come ill, have diarrhea, or become dehydrated.
MEDICAL RESIDENT (NEMCH): Because chronic
metabolic acidosis in children retards normal growth
and development, do you think there is an added
risk in using hippuric acid or mandelic acid in the
pediatric age group?
DR. E. H. KASS: We don't produce clinically ap-
parent metabolic acidosis if we can avoid it. There
is no need to do so. Our goal is simply to lower uri-
nary pH to about 5.0 without producing systemic
acidosis.
DR. SAMUEL 0. THIER (Chairman, Department
of Medicine, Yale University School of Medicine):
How do you control urinary tract infections in the
patient who has stones and renal tubular acidosis?
DR. E. H. KASS: Those are the most difficult pa-
tients. We don't know how to cope with this prob-
lem effectively and many of our failures occur in
this group. We cannot bring the urine pH down, and
the treatment we would prefer to use is likely to
make the acidosis worse. So, we try to find an ef-
fective antibiotic and rely on long-term maintenance
therapy. A major effort should be made to avoid
needless instrumentation that can introduce resist-
ant organisms.
DR. J. P. KASSIRER: How do you manage the pa-
tient who is unable to tolerate large doses of methe-
namine mandelate or hippuric acid?
DR. E. H. KASS: That is a difficult problem. It is
usually the gastrointestinal tract that rebels al-
though sometimes the dysuria becomes intolerable.
Under these circumstances, we try simply to ma-
nipulate the diet to bring about lower urinary pH
and use smaller doses of the drug. This can usually
be done by feeding more meat or, if necessary, by
adding methionine [3]. This strategy depends upon
dietary hippuric acid to clear the bacteria, and occa-
sionally it works. I once did an experiment on my-
self in which I ate meat three times a day and in-
creased my source of dietary hippuric acid by in-
gesting large amounts of fruits and oats. My urine
became very acid and when inoculated in the labo-
ratory was quite unable to support the multiplica-
tion of gram-negative rods at pH up to 5.5. Rarely,
we must use antibiotics in patients who cannot tol-
erate methenamine mandelate.
DR. J. P. KASSIRER: There has been considerable
interest recently in the use of sulfonamides in a
single daily dose at night to prevent recurrences of
infection. Could you compare your results to those
achieved with other methods of treatment such as
this one?
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DR. E. H. KASS: As you indicate, there have been
recent reports about the night time administration
of an antibacterial drug to reduce the frequency of
urinary infection. Most of these reports are based
on the assumption that infections are frequently ac-
quired as a result of sexual activity and that post-
coital doses may thus be effective. The papers are
flawed, in my opinion, by failure to consider ade-
quately alternative hypotheses. The problem starts
with the general medical perception that sexual ac-
tivity is a major determinant in the pathogenesis of
urinary tract infection in women. I suppose that this
is about as common a teaching as any there is. The
only thing wrong with this teaching is that it doesn't
agree with the facts. In every population that has
been studied, the rate of bacteriuria in women rises
linearly from about 1% in the first decade of life
through the seventh and eighth decades. If sexual
activity were a major determinant of bacteriuria,
the rate would not rise linearly but would show an
excess over linearity in the years of maximal sexual
activity. It does not. Kunin has recently reviewed
some of these problems [6].
In the age group of maximal sexual activity, the
frequency of bacteriuria at any moment averages 2
to 4%, and the turnover rate is such that roughly
four times this number will have bacteriuria at some
time over the next decade or two [7]. Thus, about
12% of women in the age group of maximal sexual
activity will have at least one urinary infection, but
such infections are most often clinically inapparent.
The infection may become apparent when there is
some inciting cause, such as local trauma to the ure-
thra. In addition, a great deal of the association that
has been observed clinically is between sexual ac-
tivity and dysuria, not urinary infection. Only about
30 to 50% of ambulatory patients with dysuria have
bacteriuria [8]. Of all patients with bacteriuria, only
about 50% have dysuria. Thus, there is a relation
between dysuria and bacteriuria but it is not a par-
ticularly strong one.
I feel strongly about the common belief that uri-
nary infection can be caused by sexual activity. Pe-
riodically, I receive phone calls from the daughters
of friends—late at night—asking if I would see them
the next day and "please don't tell my parents."
Urinary infection is not a venereal disease, despite
all the teaching of the medical profession, and it is a
great pity that knowing winks accompany the diag-
nosis of urinary infection in young women.
Women have more urinary infections than men,
as we know. The ratio is 9 to 10:1 in ambulatory,
unselected populations [7]. We don't know why the
sex difference exists. The length of urethra surely
must have something to do with it. But we don't
have any insight into the factors involved. If we
suggest that every young woman should take a post-
coital dose of an antimicrobial drug, there would
surely be fewer urinary infections. There would
surely also be fewer urinary infections if each wom-
an in this age group took such a drug without coitus,
and that is the control that is absent from all of the
studies that have been done on this problem. The
prevalence of bacteriuria is high enough that if one
simply administered an effective drug at fairly regu-
lar intervals to all women, a certain number of cases
of bacteriuria would clear and the rate of overt in-
fection would fall. I am not advocating this ap-
proach but simply pointing out the defects in studies
that show the effectiveness of post-coital anti-
microbial drugs and then use this observed ef-
fectiveness to argue that there must be a relation
between sexual activity and urinary infection.
DR. EDWIN MEARES (Chief, Urology, NEMCH):
In that regard, what about the study of Kunin and
McCormack [9] that demonstrated a significantly
lower incidence of urinary infection in nuns?
DR. E. H. KASS: That was an interesting study.
They observed that the rate at which urinary infec-
tion increased with age in a group of nuns was ex-
actly parallel to the rate of increase with age in a
group of women who were not nuns; but at each age
the rate in nuns was 1 or 2% lower than in the com-
munity at large. I think what the study is really
saying is that the reasons why women acquire uri-
nary infection are often unknown. It is likely that
circumstances of personal hygiene and other as-
pects of a woman's life contribute to the pathogene-
sis of urinary infection. Nuns are a self-selected
group and are not a random representation of the
female population. It isn't useful to compare their
rates of infection with the rates of women who are
not nuns until we know more about the particular
variables at issue. But the one variable that seems
to be irrelevant is sexual activity because it cannot
account for the steady increase with age in the fre-
quency of urinary infection in nuns.
DR. FRANCIS P. TALLY (Infectious Disease,
NEMCH): Would you comment on the use of sul-
fonamide-trimethoprim mixtures in the treatment of
recurrent urinary tract infection [10]?
DR. E. H. KASS: The sulfonamide-trimethoprim
mixture is a very useful antibacterial preparation
[11]. The mixture costs more than sulfonamide
alone but it may have a wider spectrum of activity;
the effect of trimethoprim alone ought not to be
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overlooked. But I think it is a toss-up whether to
use the mixture instead of a sulfonamide alone.
DR. F. P. TALLY: You have stated that the origins
of urinary infection in women are completely un-
known. What is your view of the studies by Stamey
et al, which suggest that the nature and persistence
of the periurethral flora may be of crucial impor-
tance [12—14]?
DR. E. H. KASS: The work of Stamey et al is very
important [15]. It should be remembered that many
of their patients were referred after having received
multiple treatments. That such treatments affect the
periurethral flora is undoubted, but we don't know
for how long the effect persists. The question re-
mains whether those data are applicable to pre-
viously untreated women. Let me only mention that
Kunin (KuNIN, personal communication, 1979) has
some more recent data that demonstrate little evi-
dence for the periurethral flora as the major de-
terminant of the bacterial flora of the infected urine
in women who don't have a past history of repeated
infections. This does not negate Stamey's data but
only indicates the complexity of the problem. What
may be true for women who have had repeated
courses of treatment may not be true for women
with unaltered periurethral flora. Only time and
more studies will tell.
DR. E. MEARES: I think it is fair to say that the
group of women Stamey studied is not as highly se-
lected as you indicate. At Stanford, the urologists
see most women who come to the emergency room
or to the outpatient clinics with urinary tract infec-
tions. Many of these women are experiencing their
first infection or have had only infrequent problems.
DR. E. H. KASS: This is one of the issues that has
to be better evaluated. It is not entirely clear from
the published data whether the patients are a select
group or not and how the findings might relate to
individual past histories.
DR. JOHN BALL (Renal Fellow, NEMCH): Is it
ever necessary to measure antibiotic concentrations
in the urine?
DR. E. H. KASS: This is not necessary with most
of the drugs that we use because in most instances
these antibiotics are excreted primarily in the urine
in an active form. The only important exception is
chloramphenicol, and even with this agent 15% is
excreted in the urine unchanged and active.
DR. MARTIN GELMAN (St. Elizabeth's Hospital,
Brighton, Massachusetts): In treating women with
sporadic urinary tract infection, what are your
thoughts about using a single dose of an antibiotic
such as amoxicillin?
DR. E. H. KA55: This relates to an old principle
that is rediscovered every few years. We have
known all along that a certain number of patients do
not have evidence of involvement of the upper uri-
nary tract. Those patients who have involvement of
the upper urinary tract are generally more difficult
to clear than those whose infections seem to be lim-
ited to the lower urinary tract. Those people who
have lower urinary tract infection may be cleared
by a single large dose or by repeated small doses. It
amounts to the same thing. The problem is knowing
how to proceed with a given patient. I have no quar-
rel with the idea of giving the patient 1 or 2 days of
treatment and reculturing the urine. I do that regu-
larly. It is an inexpensive and effective way to de-
termine whether a patient will respond promptly.
The important point is to reculture after treatment
because 10 to 20% of infections will reappear imme-
diately after treatment has been discontinued.
DR. J. J. COHEN: Considerable emphasis has
been placed recently on the value of differentiating
between bladder and upper urinary tract infections.
Do you think this is an important issue clinically
and, if so, how do you go about it?
DR. E. H. KASS: From a research point of view,
there is no question about the desirability of obtain-
ing data on the localization of urinary infections. At
the moment, I think there are two ways of doing
this. On the pragmatic clinical level, at the present
state of our knowledge, the cheapest and most ef-
fective approach is to treat and reculture the urine 1
or 2 days later. There are people, however, who
have evidence of upper urinary tract infection but
respond promptly to treatment and remain clear for
varied periods of time after treatment is discontin-
ued. On the other hand, there are people who have
no apparent evidence of upper tract involvement
and yet get prompt recurrence of the infection after
treatment. So the response to treatment may be
helpful in differentiating between upper and lower
tract infection but there is a substantial overlap be-
tween the two groups [16]. Please keep in mind that
the earlier studies, using various localizing tests,
show a statistical but not an absolute relation be-
tween localization and response to treatment.
The second and more recent approach is based on
the antibody coating test. Unfortunately, there are
technical problems in detecting antibody coating
and there is no agreement in the literature as yet on
the end point of the measurement. What percentage
of bacteria must be coated before the preparation is
called positive? Depending on the answer to this
question, there will be different levels of correlation
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with localization studies and with response to treat-
ment. At the moment, I do not believe antibody
coating is as effective a clinical tool as a careful
evaluation of the patient's response to treatment.
The published data on correlation between antibody
coating and response to treatment relate to remark-
ably small experiences. It will be wise to wait for
more data.
DR. M. GELMAN: You clearly put less stock in
the antibody coating of bacteria than others do.
DR. E. H. KASS: Our series is different from most
of the others because it consists of women who
were found to be bacteriuric in household surveys
and because the series is large. Most clinics and of-
fices filter out certain groups of patients and pass
along only a relatively small fraction to hospitals
and referral clinics. Most published reports contain
a fair number of people who have repeated episodes
of infection. We don't have accurate random figures
except as I quoted them earlier. There is no particu-
lar validation of any figure, so far, in the literature.
The test needs more rigorous standardization, prob-
ably in a large multicenter cooperative study, and
more evaluation on a larger scale.
DR. JAMES STROM (Renal Fellow, NEMCH):
When you use moderately high doses of methena-
mine mandelate in long-term treatment, do you give
the drug twice a day or four times a day?
DR. E. H. KASS: We recommend a four times a
day schedule because of convenience and patient
acceptance.
DR. J. STROM: Do you ever use methenamine
mandelate in the treatment of uncomplicated first
urinary tract infections?
DR. E. H. KASS: No, it is too cumbersome. One
can treat so effectively with more convenient oral
drugs that these are preferred.
DR. E. MEARES: You indicated that the mandelic
acid, not the methenamine, was the effective in-
gredient in the Mandelamine preparation. Have you
actually treated patients with pure mandelic acid
without the methenamine?
DR. E. H. KASS: We have treated patients with
pure hippuric acid with good results.
DR. E. MEARES: Then why give methenamine at
all?
DR. E. H. KASS: It is given only because it is part
of the commercial preparation.
DR. E. MEARES: I raise the question because with
the large doses that you use there may be enough
formaldehyde released to cause bladder irritation in
patients who void infrequently.
DR. E. H. KASS: The amount of free formal-
dehyde is so variable that we ought to disregard it
and depend on the organic acid components. Con-
siderable time and effort has been expended in
trying to get better measurements of formaldehyde
in urine, but there is still a lot of uncertainty about
what is being measured. It is clear that the amounts
are not uniform in response to relatively constant
conditions of drug dosage, presumably reflecting
variations in the amount of other compounds that
react with formaldehyde. When we first encountered
the antibacterial effect of cranberry juice, we re-
alized the active component in the urine was hip-
puric acid. Our paper on this with Drs. Bodel and
Cotran showed the results of treating with hippuric
acid alone [3]. Pure mandelic acid is not marketed
but is readily available at low cost in combination
with methenamine.
DR. J. T. HARR!NGTON: An interesting point illus-
trated by this patient is that even repeated severe
urinary tract infections do not necessarily result in
end-stage renal failure. What is your present view
about the role of urinary tract infection as an an-
tecedent to chronic renal insufficiency?
DR. E. H. KASS: Let me run through the numbers
to help clarify what is sometimes a muddied situa-
tion. The estimated rate of renal failure often used
for planning purposes in relation to dialysis and
transplant programs is approximately 50 new cases
per million per year. This figure is an underestimate
because it does not include those patients who are
deemed to be ineligible for such programs. So, we
don't know the true rate of renal failure but it is
clearly higher than 50 cases per million per year.
We can take this figure, however, as a point of de-
parture. We find in various autopsy series that no
more than approximately 40% of kidneys have a le-
sion that might conceivably be classified as pyelo-
nephritis.
Using 40% as a maximum figure for pyelonephri-
tis, we are already down to only 20 cases per mil-
lion per year as the maximum possible rate of renal
failure due to pyelonephritis, and it would be silly
to argue that all of the lesions that could be py-
elonephritis are bacterial in origin, given all the
other reasons for similar renal lesions. Even at the
improbable maximum yearly number of 20 cases
per million due to pyelonephritis, the rate of bacte-
riuria is in the order of 100,000 cases per million, so
that 20 cases per year of renal failure would be the
maximum and the improbable expectation for every
100,000 patients with bacteriuria. You can do your
own arithmetic from that point. The problem cannot
be solved epidemiologically because it is unlikely
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that anyone will fund studies involving many hun-
dreds of thousands of bacteriuric individuals. The
problem can be solved by collecting individual cas-
es. It is a matter of going back to each case as the
kidneys deteriorate in some and not in others and
trying to put together the natural history of the dis-
ease. But in any event, the incidence of renal failure
following infection is finite but small [17].
DR. J. J. COHEN: Do you have any feeling for
what factors are important in determining which
bacteriuric patients progress to chronic renal in-
sufficiency?
DR. E. H. KASS: No. Be wary of many of the
studies in the literature. They often exclude from
consideration many patients with "underlying dis-
ease" without regard for whether these underlying
disorders are a possible consequence of infection.
DR. J. J. COHEN: You commented earlier on how
difficult it is to acidify the urine in patients infected
with Proteus or other urea-splitting organisms. Is
there any way of getting around this problem by in-
hibiting urease in the urine?
DR. E. H. KASS: Yes, there are several com-
pounds that have been used through the years to
inhibit urease. They have never been explored on a
large scale. Unfortunately, they tend to be rather
toxic. Some patients who receive these compounds
seem to clear their Proteus, and I have never under-
stood that. I have no personal experience with these
substances.
DR. J. J. COHEN: It is well recognized that bac-
teria can disappear from the urine spontaneously in
patients with both symptomatic as well as asympto-
matic bacteriuria. In view of this, I wonder whether
some of the apparent successes with your step-wise
protocol of increasing the dose of methenamine
mandelate over protracted periods of time may re-
flect the natural history of the urinary infection
rather than a response to therapy.
DR. E. H. KASS: The spontaneous clearing rate of
bacteriuria is about 20 to 25% per year, but we don't
have good data on whether age influences this [7]. I
have a feeling that the rate of clearing is different for
different age groups but this hasn't been well stud-
ied. We now know that the rate of turnover of bac-
teriuria is slowed for women who are taking an oral
contraceptive [18]. The prevalence of bacteriuria is
demonstrably higher in such women because they
retain their bacteriuria for a longer period of time.
This is the only effect we could find with oral con-
traceptives in relation to urinary infection. This is
also the only circumstance so far in which a dif-
ference in turnover time has been shown to be an
important variable. I suspect that part of the reason
for the higher prevalence of bacteriuria as women
get older is that the spontaneous clearing of bacte-
riuria occurs more slowly, but there is no proof of
this. In general, the turnover time is such that bac-
teriuria clears spontaneously at a rate of about 2%
per month or about 0.5% per week [7]. So one can
calculate that with most treatments one is ex-
ceeding by far the rate of clearing that would come
from spontaneous turnover. But some spontane-
ous clearing obviously goes on.
Reprint requests to Dr. dward H. Kass, Channing Laborato-
ry, Longwood Avenue, Boston, Massachusetts.
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